A detailed history of Syntax Advisors, LLC transactions in Incyte Corp stock. As of the latest transaction made, Syntax Advisors, LLC holds 3,621 shares of INCY stock, worth $251,297. This represents 0.36% of its overall portfolio holdings.

Number of Shares
3,621
Previous 3,776 4.1%
Holding current value
$251,297
Previous $235,000 11.06%
% of portfolio
0.36%
Previous 0.36%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$57.77 - $65.93 $8,954 - $10,219
-155 Reduced 4.1%
3,621 $209,000
Q2 2023

Aug 14, 2023

BUY
$60.95 - $75.51 $27,305 - $33,828
448 Added 13.46%
3,776 $235,000
Q1 2023

May 15, 2023

BUY
$70.23 - $86.01 $27,600 - $33,801
393 Added 13.39%
3,328 $240,000
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $42,054 - $52,652
-626 Reduced 17.58%
2,935 $235,000
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $9,927 - $12,429
150 Added 4.4%
3,561 $237,000
Q2 2022

Aug 12, 2022

BUY
$66.18 - $83.18 $20,184 - $25,369
305 Added 9.82%
3,411 $259,000
Q1 2022

May 11, 2022

SELL
$66.02 - $79.71 $57,635 - $69,586
-873 Reduced 21.94%
3,106 $247,000
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $252,029 - $294,883
3,979 New
3,979 $292,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.4B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Syntax Advisors, LLC Portfolio

Follow Syntax Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Syntax Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Syntax Advisors, LLC with notifications on news.